Sat, Sep 20, 2014, 6:43 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

The Advisory Board Company Message Board

thekindaguyiyam 20 posts  |  Last Activity: Sep 5, 2014 4:03 AM Member since: Jun 7, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • thekindaguyiyam thekindaguyiyam Sep 5, 2014 4:03 AM Flag

    have you really been posting on YMB since yesterday? With no reference to validate I must guess that you are wasting my time with speculative noise. IggyZone is where you belong and where I'm sending you. It was the expectation of a buy out presented by fool shorts that missed that expectation resulting in them sending the stock downward. Pump or Bash is the same noise. I'm very long and have no place in the world for idjits like you.

    Sentiment: Strong Buy

  • Reply to

    Be honest Would you buy right here now????

    by joefroger Jun 27, 2014 1:56 PM
    thekindaguyiyam thekindaguyiyam Sep 3, 2014 11:09 AM Flag

    Mannkind is alive. It's you who is brain dead. IggyZone for you zombie.

    Sentiment: Strong Buy


  • MannKind (NASDAQ:MNKD) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 77,343,842 shares, an increase of 6.6% from the July 31st total of 72,584,807 shares, American Banking News reports. Based on an average daily trading volume, of 17,109,430 shares, the days-to-cover ratio is currently 4.5 days. Approximately 31.0% of the company’s shares are sold short.
    Several analysts have recently commented on the stock. Analysts at Jefferies Group initiated coverage on shares of MannKind in a research note on Wednesday. They set a “buy” rating and a $10.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of MannKind in a research note on Wednesday, August 13th. They now have a $7.75 price target on the stock. Finally, analysts at RBC Capital cut their price target on shares of MannKind from $16.00 to $13.00 in a research note on Tuesday, August 12th. They now have an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. MannKind currently has an average rating of “Hold” and an average target price of $9.36.

    When I look at the MNKD Proboard a sampling of long ownership is significant. I am a Long.
    Technospere is bigger than most people can imagine. When Afrezza is proven as the most effective way to distribute medication; this will be the initial confidence needed to successfully
    launch the platform for many other illnesses from chronic pain to cancer. IMHO Technosphere is not for sale… and Afrezza will be a blockbuster drug as a result of it's delivery system. Sanofi is the right company who's distribution system is 120 countries.

    Sentiment: Strong Buy

  • Reply to

    MANKINDERS are a CULT

    by jimbeam275 Aug 25, 2014 1:35 PM
    thekindaguyiyam thekindaguyiyam Aug 25, 2014 9:15 PM Flag

    this from a genius who names himself after a bottle of booze. IggyZone 4 you noise maker.

    Sentiment: Strong Buy

  • Reply to

    They pumped it and now they're DUMPing it

    by permit.20841 Aug 25, 2014 3:49 PM
    thekindaguyiyam thekindaguyiyam Aug 25, 2014 4:53 PM Flag

    permit.20841
    426 posts | Last Activity: 47 minutes ago
    Member since: Jul 25, 2014

    that's a lot of posts in one month since initiating your account with YMB.
    Clearly your caring for the well being of other investors and the world community at large
    shows the compassion to help us all in being safe and secure as per your constant concerns
    of the sky is falling. I will personally let other's know on other message boards that you are my
    candidate for the Pulitzser Peace Prize. After all! You already have a permit. Stock manipulation
    is a crime; and as such, there is a special place for people like you who speak without knowing and that's where you are going right now. It's called THE IGGYZONE. see ya in another lifetime chitforbrains.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Aug 22, 2014 2:18 PM Flag

    You REALLY HAVE NO CLUE as to what you are talking about. 35% X 120 countries with 1/3 of each population being pre diabetic or have diabetes. Establishing this partnership will exceed the expectations of long term investments and possibly short term.. 4 - 8 weeks or less as the details of the partnership are exposed. The not knowing gives shorts the smokescreen to cover their organized practices to drop the price
    and then repurchase the stock.

    In that you are a total idiot and fool; you have no worthwhile information for the investment community and supply only speculative noise that I am turning off right now. IggyZone for you. Click

    Sentiment: Strong Buy

  • Reply to

    THIS IS A CULT STOCK

    by ishortu Aug 21, 2014 8:16 PM
    thekindaguyiyam thekindaguyiyam Aug 21, 2014 9:53 PM Flag

    1. the shorts are into mnkd as a commodity not a long term investment thus they are called shorts.

    2. The longs will be satisfied by their investment because they aren't looking at it as a short term commodity investment but instead a new delivery system for a drug that will help 1/3 of the worlds population.

    3 Sanofi the French Bio Pharm which is the biggest seller and distributor of insulin in the world with distribution in 120 countries will pay for 65% of Research and Development costs and the 35% that MNKD gets from Afrezza the first drug to test the success of technospere has hundreds of patents that will insure an incredible future for MNKD of which SNY has no ownership in… no ownership in technospere; just Afrezza with also supports another of Mr. Mann's inventions which is the insulin pump.

    4. You have no clue. You are a totally ignorant in the most significant way because you don't understand the #'s of potential market share to a worlds population which will result in the acceptance of the medical community to use Technospere in hundreds of applications making really big bucks while helping out humanity and mankind.

    With this I put you in the Iggy Zone because your BS is just noise from someone who doesn't know what he is talking about.

    Sentiment: Strong Buy

  • Reply to

    opinions

    by helpallaretaken Aug 4, 2014 6:03 PM
    thekindaguyiyam thekindaguyiyam Aug 4, 2014 7:34 PM Flag

    Institutes own 21.56% of all shares. Look it up. Now back to the iggy zone for you
    cause you try to manipulate instead of research.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Aug 3, 2014 9:58 PM Flag

    very poor effort at a bash. Is Mann Kind? Absolutely. He has contributed to the world in major way benefiting people who have diseases of hearing, blindness, diabetes and many many more patents. His money received goes into a philanthropic fund to help people.

    What have you done. Never mind I don't care. The iggy zone is where you belong cause if you are investing in a company with a CEO you don't respect you have to be an absolute idiot. Move on.

    Sentiment: Strong Buy

  • Reply to

    EARNINGS REPORT 08/08/2014

    by diner69er Aug 3, 2014 9:15 PM
    thekindaguyiyam thekindaguyiyam Aug 3, 2014 9:53 PM Flag

    there is no information that suggests that date on the Mannkind webpage. Until they list, it ain't so.

    Sentiment: Strong Buy

  • Reply to

    A note to Al Mann

    by pokeysun Jul 26, 2014 12:09 PM
    thekindaguyiyam thekindaguyiyam Jul 26, 2014 3:33 PM Flag

    most people still have no clue what technosphere is and the patents approved for it's "revolutionary" delivery. system (FDA) The shorts what you to think that Afrezza is Exubra. It is not. 1/3 of the worlds population are diabetic or pre diabetic. Next technospere drug delivery for pain; a bigger market than for diabetes.
    ALFRED MANN is a the Tesla in our lifetime.

    Sentiment: Strong Buy

  • Reply to

    Dead Money In A Raging Bull Market

    by jewhader3 Jul 16, 2014 10:49 AM
    thekindaguyiyam thekindaguyiyam Jul 16, 2014 11:00 AM Flag

    your name says it all. You are a sick #$%$. I have no room for nazis in my world. Goodbye forever. IggyZone for you and your puny little mind.

    Sentiment: Strong Buy

  • Reply to

    Guess I was wrong

    by stockwatcher7504 Jul 16, 2014 9:40 AM
    thekindaguyiyam thekindaguyiyam Jul 16, 2014 10:56 AM Flag

    your lack of patience is based in lack of confidence that your expectations didn't manifest in your own subjective time frame. ADA overwhelmingly positive. FDA approval weeks before deadline. Shares have dried up. Alfred Mann's Namesake company is on the edge of announcement. And you; either a fool, afraid and or have alternative motives because of life not going exactly as you planned. Now; that's just stupid; cause life rarely delivers exactly what we want in the time frame we want it. If you don't have the patience then you might want to invest in typewriters. I'm not here to hold your hand. I'm here to make money on a delivery system called technospere that will deliver an inhaled ultra fast insulin that will provide comfort, and improvement in the lives of 1/3 of the worlds population. Since I spend my time on worthy posts and read endlessly on a daily bases for my affirmation in my investments; it's clear to me that what you offer doesn't add to my knowledge base. Therefore; off you go to the Iggy Zone. Enjoy!

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jul 11, 2014 10:43 PM Flag

    tell em what they want; but, technospere is not for sale. Afrezza is. Dreamboat deliver's the first technosphere delivery of the 1st of hundreds of patents. All of those patents and the "revolutionary new delivery system" is not for sale. I am long holding many shares and calls. You may think you know what the company is going to do; but from my perspective your have it wrong. Afrezza will be partnered. MNKD will continue to manufacture it in Danbury but the marketing will be a partnership with a global pharm. The next drug out using the technosphere delivery after afrezza's proven success will be a drug next spring for people with chronic pain which is 4X the population of Diabetes. My friend; you have to do more research... technosphere is a diamond mine that is not for sale. If you can prove otherwise; I'd be happy to acknowledge your subjective allegation.

    Sentiment: Strong Buy

  • NEW YORK (AVAFIN) -- Options traders were heavily trading call contracts during the last trading session establishing a new 3-month call volume record. A total of 5,777 put and 17,481 calls were traded where call contracts outnumbered puts 3.0:1, yielding a 0.33 ratio.
    Options are useful tools for predicting the movement of the underlying stock. Put/Call ratio statistics serve as a useful predictor of investment sentiment, indicating what experienced investors are doing in preparation for a move of an underlying stock. Thus, unusual volume provides reliable clues that the stock is expected to make a move.
    Shares of MNKD closed at $10.07 during the previous session. During the session, the stock hit a low of $9.81 and high of $10.10. The current trading volume of 5.04M is less than average volume of 13.69M shares. MNKD is trading above the 50 day moving average and higher than the 200 day moving average. The stock's 52 week low is $3.80 and 52 week high is $11.48. To date, the stock has gained 0.10% within the last week.
    MannKind Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jul 6, 2014 1:15 PM Flag

    so you are saying that mankind leaked a story. no proof just pump. Friend; I am very LONG.
    What you say is true on one level. MNKD will partner up with a Global Pharmaceutical company and it is only a matter of time. This conclusion requires no genius. I hate those guys who create the FUD and I don't care for pumpers much either. Just give us provable facts; that's all what any INVESTOR wants.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jul 6, 2014 11:21 AM Flag

    yours isn't worth reading. ignore list for you; you waste our time with noise.

    Sentiment: Strong Buy

  • Reply to

    Go to Webmd and search Afrezza FAQ

    by radgray68 Jul 2, 2014 1:26 AM
    thekindaguyiyam thekindaguyiyam Jul 2, 2014 1:03 PM Flag

    June 30, 2014 -- Millions of people with type 1 or type 2 diabetes will have another treatment option now that the FDA has approved an inhaled insulin.

    Called Afrezza, the rapid-acting insulin is taken before each meal, or soon after starting to eat, with no needles required. Afrezza won't replace the need for injected long-acting insulin for those who need it, though.

    WebMD asked diabetes experts about this newest option:

    How is Afrezza different than other insulin?

    Because it's inhaled, it's absorbed more quickly and in a different way.

    "Afrezza is rapidly absorbed from the cells in the lungs [to the blood stream]," says R. Keith Campbell, RPh. He's a certified diabetes educator and distinguished professor emeritus in diabetes care and pharmacotherapy at Washington State University College of Pharmacy. He has studied the drug but has no ties to its developer.

    "From the time you inhale it to the time it actually peaks [in the blood] is 15 to 20 minutes," Campbell says. Injected insulin taken before a meal, he says, takes about an hour to peak.

    The body also clears Afrezza more quickly than insulin injected at mealtime, says Bruce Bode, MD. He's a diabetes specialist in Atlanta who did a clinical trial funded by MannKind Corporation, the drug’s developer.
    Besides its rapid peak, the drug is ''pretty much gone in 2 or 3 hours," Bode says. Rapid-acting injected insulins, he says, usually ''hang around for about 4 hours. Afrezza is fast in, fast out. It is emulating, in essence, what the pancreas does."

    How is it taken?

    Users place a dose of Afrezza, in powder form, into a small, whistle-sized inhaler. Doses come in a cartridge, and each cartridge contains a single dose.
    How does Afrezza work compared to rapid-acting injected insulins?
    In a 24-week study, Bode compared Afrezza with a rapid-acting, injected insulin in more than 500 patients with type 1 diabetes. Afrezza and injected insulin controlled blood sugar equally well, he says. continues...

    Sentiment: Strong Buy

  • Reply to

    Fullshred's post from iHub

    by yeffrey22 Jul 2, 2014 12:08 PM
    thekindaguyiyam thekindaguyiyam Jul 2, 2014 12:57 PM Flag

    good analysis of the situation. remarkable too that the shorts wildly control the price and know very little about diabetes or give a dam about the remedy assisting a huge population. To the shorts Afrezza is a commodity in which they can manipulate with the help of Cramer and his cronies to make as much money as possible. Money is the market goal. Remedy is the goal of the science of Mannkind.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jun 29, 2014 4:36 PM Flag

    Techosphere has been accepted by the FDA. Technosphere is the delivery system while DreamBoat is the disposable apparatus. Afrezza is the First Technosphere delivery. The next patent coming before the FDA is from MNKD in spring of next year for people with Chronic Pain which is a non narcotic. Population of that market is 4X's that of Afrezza's Diabetes Meds. Now add another 400 -700 patents for ultra fast delivery for many other diseases and you will get a glimpse of what Technospere from Mannkind really is; a paradigm shift for improved delivery and much much faster. Me? I'll sell when Alfred sells.

    Sentiment: Strong Buy

ABCO
47.01-1.45(-2.99%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.